Low-molecular-weight heparin for the prevention and treatment of venous thromboembolism in pregnancy

2004 ◽  
Vol 10 (5) ◽  
pp. 371-375 ◽  
Author(s):  
M D McColl ◽  
I A Greer
Keyword(s):  
Molecular Weight ◽  
Venous Thromboembolism ◽  
Low Molecular Weight Heparin ◽  
Low Molecular Weight ◽  
Prevention And Treatment ◽  
In Pregnancy

scholarly journals Thromboembolism and antithrombotic management in pregnancy

2011 ◽  
Vol 152 (21) ◽  
pp. 815-821 ◽  
Author(s):  
Attila Pajor
Keyword(s):  
Risk Factors ◽  
Molecular Weight ◽  
Venous Thromboembolism ◽  
Low Molecular Weight Heparin ◽  
Oral Anticoagulants ◽  
Individual Risk ◽  
Low Molecular Weight ◽  
Pregnancy And Delivery ◽  
Individual Risk Factors ◽  
In Pregnancy

Venous thromboembolism occurs approximately in 1 of 1000 pregnancies. It is one of the leading causes of maternal mortality. Physiologic changes associated with pregnancy and delivery favor for developing venous thromboembolism, and there are individual risk factors, too, contributing to its manifestation. The most frequent risk factors of venous thromboembolism developing during pregnancy are the previous venous thromboembolism and the thrombophilias, furthermore, some other diseases and some unique complications of pregnancy and delivery. Beyond mechanical prevention only heparin preparations can be used for preventing and treating venous thromboembolism in pregnancy and among them the low-molecular-weight heparins are preferred for applying. Dosage of low-molecular-weight heparin preparations is determined by the type and strength of thrombophilia. For treatment of venous thromboembolism presented during pregnancy subcutaneous 100 IU/kg low-molecular-weight heparin is generally used at every 12 hours. Postpartum the oral anticoagulants can be safely applied, too. Orv. Hetil., 2011, 152, 815–821.

The management of thrombosis in pregnancy: Role of low-molecular-weight heparin

2007 ◽  
Vol 97 (04) ◽  
pp. 505-513 ◽  
Author(s):  
André Kher ◽  
Jorn Nielsen ◽  
Rupert Bauersachs
Keyword(s):  
Molecular Weight ◽  
Pregnancy Complications ◽  
Low Molecular Weight Heparin ◽  
Vitamin K Antagonists ◽  
Fetal Loss ◽  
Late Pregnancy ◽  
Low Molecular Weight ◽  
Prevention And Treatment ◽  
In Pregnancy

SummaryFatal pulmonary embolism remains the most common cause of mortality among pregnant women in many Western countries. The physiological changes of pregnancy produce a hypercoagulable state that increases the risk of venous thromboembolism (VTE).Women with inherited or acquired thrombophilias are at particularly high risk of VTE during pregnancy, and thromboprophylaxis may be advisable in some cases. Thrombophilia is also associated with complications of pregnancy, including fetal loss, pre-eclampsia, intra-uterine growth restriction, and placental abruption. The antithrombotic agents available for the prevention and treatment of VTE during pregnancy, and pregnancy complications, include unfractionated heparin (UFH), low-molecular-weight heparin (LMWH) and aspirin. Vitamin K antagonists are contra-indicated in pregnancy. Low-dose aspirin may have a role in the prevention of some pregnancy complications, although its safety in early and late pregnancy is uncertain. The efficacy and safety of LMWHs have been demonstrated for the prevention and treatment of VTE in pregnancy. These agents are increasingly being used in place of UFH, which is associated with a higher incidence of side effects compared with LMWH, in addition to the need for regular laboratory monitoring. Evidence is also emerging to support the use of LMWH in the prevention of recurrent fetal loss, although further trials are needed to explore the role of LMWHs in this indication and in the prevention of other complications of pregnacy.

scholarly journals Pulmonary thrombo-embolism in pregnancy: diagnosis and management

Breathe ◽  
2015 ◽  
Vol 11 (4) ◽  
pp. 282-289 ◽  
Author(s):  
Louise E. Simcox ◽  
Laura Ormesher ◽  
Clare Tower ◽  
Ian A Greer
Keyword(s):  
Molecular Weight ◽  
Venous Thromboembolism ◽  
Low Molecular Weight Heparin ◽  
Pulmonary Thromboembolism ◽  
Total Duration ◽  
Bleeding Risk ◽  
Low Molecular Weight ◽  
List Type ◽  
Diagnosis And Management ◽  
In Pregnancy

Key pointsVenous thromboembolism (VTE) in pregnancy remains a leading cause of direct maternal mortality in the developed world and identifiable risk factors are increasing in incidence.VTE is approximately 10-times more common in the pregnant population (compared with non-pregnant women) with an incidence of 1 in 1000 and the highest risk in the postnatal period.If pulmonary imaging is required, ventilation perfusion scanning is usually the preferred initial test to detect pulmonary embolism within pregnancy. Treatment should be commenced on clinical suspicion and not be withheld until an objective diagnosis is obtained.The mainstay of treatment for pulmonary thromboembolism in pregnancy is anticoagulation with low molecular weight heparin for a minimum of 3 months in total duration and until at least 6 weeks postnatal. Low molecular weight heparin is safe, effective and has a low associated bleeding risk.Educational aimsTo inform readers about the current guidance for diagnosis and management of pulmonary thromboembolism in pregnancy.To highlight the risks of venous thromboembolism during pregnancy.To introduce the issues surrounding management of pulmonary thromboembolism around labour and delivery

Low Molecular Weight Heparin for the Treatment of Venous Thromboembolism in Pregnancy: A Case Series

2003 ◽  
Vol 58 (3) ◽  
pp. 153-155
Author(s):  
V. A. Rodie ◽  
A. J. Thomson ◽  
F. M. Stewart ◽  
A. J. Quinn ◽  
I. D. Walker ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Venous Thromboembolism ◽  
Low Molecular Weight Heparin ◽  
Case Series ◽  
Low Molecular Weight ◽  
In Pregnancy
Sign in / Sign up

Export Citation Format

Share Document